| ［1］ |
Gooderham M, Posso⁃De Los Rios CJ, Rubio⁃Gomez GA, et al. Interleukin⁃17 （IL⁃17） inhibitors in the treatment of plaque psoriasis: a review［J］. Skin Therapy Lett, 2015,20（1）:1⁃5.
|
| ［2］ |
Burkett PR, Kuchroo VK. IL⁃17 blockade in psoriasis［J］. Cell, 2016,167（7）:1669. doi: 10.1016/j.cell.2016.11.044.
|
| ［3］ |
李祥, 张小艳, 张理涛. 生物制剂治疗银屑病药物选择［J］. 中国中西医结合皮肤性病学杂志, 2019,18（1）:35⁃38. doi: 10. 3969/j.issn.1672⁃0709.2019.01.011.
|
| ［4］ |
Lockwood SJ, Prens LM, Kimball AB. Adverse reactions to biologics in psoriasis［J］. Curr Probl Dermatol, 2018,53:1⁃14. doi: 10.1159/000478072.
|
| ［5］ |
尹莉, 尹志强. 白介素⁃17家族与银屑病［J］. 中国麻风皮肤病杂志, 2017,33（1）:59⁃61.
|
| ［6］ |
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis⁃⁃results of two phase 3 trials［J］. N Engl J Med, 2014,371（4）:326⁃338. doi: 10.1056/NEJMoa1314258.
|
| ［7］ |
van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long⁃term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis［J］. J Am Acad Dermatol, 2016,75（1）:83⁃98.e4. doi: 10.1016/j.jaad.2016.03.024.
|
| ［8］ |
McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti⁃interleukin⁃17A monoclonal antibody, in patients with psoriatic arthritis （FUTURE 2）: a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2015,386（9999）:1137⁃1146. doi: 10.1016/S0140⁃6736（15）61134⁃5.
|
| ［9］ |
Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate⁃to⁃severe plaque psoriasis［J］. N Engl J Med，2016，375（4）:345⁃356. doi:10.1056/NEJMoa1512711
|
| ［10］ |
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis［J］. N Engl J Med, 2015,373（14）:1318⁃1328. doi: 10.1056/NEJMoa1503824.
|
| ［11］ |
Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate⁃to⁃severe plaque psoriasis: a systematic review and meta⁃analysis［J］. Clin Drug Investig, 2017,37（5）:439⁃451. doi: 10.1007/s40261⁃017⁃0500⁃9.
|
| ［12］ |
Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin⁃17 inhibitors and their practical management［J］. Br J Dermatol, 2017,177（1）:47⁃62. doi: 10.1111/bjd.15015.
|
| ［13］ |
Leonardi C, Matheson R, Zachariae C, et al. Anti⁃interleukin⁃17 monoclonal antibody ixekizumab in chronic plaque psoriasis［J］. N Engl J Med, 2012,366（13）:1190⁃1199. doi: 10.1056/NEJMoa 1109997.
|
| ［14］ |
Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double⁃blind, placebo⁃controlled study of brodalumab in patients with moderate⁃to⁃severe plaque psoriasis［J］. Br J Dermatol, 2016,175（2）:273⁃286. doi: 10.1111/bjd.14493.
|
| ［15］ |
Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment［J］. J Am Acad Dermatol, 2014,71（6）:1183⁃1190.e3. doi: 10.1016/j.jaad. 2014.08.039.
|
| ［16］ |
Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52⁃week, open⁃label study［J］. Br J Dermatol, 2017,176（3）:741⁃751. doi: 10.1111/bjd.14702.
|
| ［17］ |
Kamata M, Tada Y. Safety of biologics in psoriasis［J］. J Dermatol, 2018,45（3）:279⁃286. doi: 10.1111/1346⁃8138.14096.
|
| ［18］ |
Smith E, Stark MA, Zarbock A, et al. IL⁃17A inhibits the expansion of IL⁃17A⁃producing T cells in mice through "short⁃loop" inhibition via IL⁃17 receptor［J］. J Immunol, 2008,181（2）:1357⁃1364. doi: 10.4049/jimmunol.181.2.1357.
|
| ［19］ |
Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin⁃17 inhibition: role in psoriasis and inflammatory bowel disease［J］. J Dermatolog Treat, 2018,29（1）:13⁃18. doi: 10.1080/09546634. 2017.1329511.
|
| ［20］ |
王刚. 皮肤科生物制剂的主要不良反应及对策［J］. 中华皮肤科杂志, 2019,52（2）:77⁃80. doi: 10.3760/cma.j.issn.0412⁃4030. 2019.02.001.
|
| ［21］ |
Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti⁃interleukin⁃17⁃receptor antibody for psoriasis［J］. N Engl J Med, 2012,366（13）:1181⁃1189. doi: 10.1056/NEJMoa1109017.
|
| ［22］ |
AbuHilal M, Walsh S, Shear N. The role of IL⁃17 in the pathogenesis of psoriasis and update on IL⁃17 inhibitors for the treatment of plaque psoriasis［J］. J Cutan Med Surg, 2016,20（6）:509⁃516. doi: 10.1177/1203475416651605.
|
| ［23］ |
Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice［J］. Rheumatology （Oxford）, 2016,55（2）:210⁃220. doi: 10.1093/rheumatology/kev277.
|
